Medicine Press release

Japan Community Healthcare Organization Osaka Hospital (JCHO Osaka Hospital), Fujitsu Japan Limited, and Fortience Consulting Inc. today announced the commencement of a project aimed at establishing a system for the safe utilization of generative AI across all medical operations at JCHO Osaka Hospital.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW).
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW).
More info..

Meiji Co., Ltd. and Fujitsu Limited today announced the start of a pilot project towards the social implementation of rRAFU(TM) [1] (Rapid Risk Assessment Tool for Future Undernutrition Status), the world's first [2] indicator to predict future risks of malnutrition and frailty (developed by Meiji.) The pilot will focus on residents aged 60 and over in Kawasaki City, Kanagawa Prefecture.
More info..

Meiji Co., Ltd. and Fujitsu Limited today announced the start of a pilot project towards the social implementation of rRAFU(TM) [1] (Rapid Risk Assessment Tool for Future Undernutrition Status), the world's first [2] indicator to predict future risks of malnutrition and frailty (developed by Meiji.) The pilot will focus on residents aged 60 and over in Kawasaki City, Kanagawa Prefecture.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of "LEQEMBI(R)" (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly(R) in the EU) in Japan.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly(R) in the EU) in Japan.
More info..

Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.
More info..

TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all processes in the contract manufacturing business for various test kits including in vitro diagnostics.
More info..